Physician profile
David M Brey
NPI 1114962362
$1,625.32
in general payments reported to CMS, 2019-2025
15 companies · $534 in 2025
The $534 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $401 · 2020: $101 · 2021: $160 · 2022: $31.76 · 2023: $25.98 · 2024: $371 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $931.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $550.27 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Abbvie INC. | $279.77 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $183.78 | 2019-2025 | Orencia |
| Janssen Biotech, INC. | $179.61 | 2019-2024 | Tremfya |
| Ucb, INC. | $73.38 | 2024-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $70.73 | 2024-2025 | Lupkynis |
| Celgene Corporation | $55.28 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $43.38 | 2025 | Saphnelo |
| Glaxosmithkline, LLC. | $35.30 | 2019-2025 | Benlysta |
| Mallinckrodt Hospital Products INC. | $34.99 | 2025 | Acthar |
| Lilly USA, LLC | $32.95 | 2019 | |
| Pfizer INC. | $31.95 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $25.98 | 2023 | Strensiq |
| Novartis Pharmaceuticals Corporation | $16.37 | 2021 | |
| Radius Health, INC. | $11.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.